Image For Activity Cover
Journal Review: Metabolic syndrome and peripheral neuropathy
Journal Review: Metabolic syndrome and peripheral neuropathy

Diabetic peripheral neuropathy and metabolic syndrome (MetS) are both global health challenges with well-established diagnostic criteria and significant impacts on quality of life. Clinical observations, epidemiologic evidence, and animal models of disease have strongly suggested MetS is associated with an elevated risk for crypto-genic sensory peripheral neuropathy (CSPN). MetS neuropathy preferentially affects small unmyelinated axons early in its course, and it may also affect autonomic and large fibers. CSPN risk is linked to MetS and several of its components including obe-sity, dyslipidemia, and prediabetes. MetS also increases neuropathy risk in patients with established type 1 and type 2 diabetes. In this review we present animal data regarding the role of inflammation and dyslipidemia in MetS neuropathy pathogene-sis. Several studies suggest exercise-based lifestyle modification is a promising treat-ment approach for MetS neuropathy.

The AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AANEM designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit expires 3/1/2024.

No one involved in the planning of this CME activity had any relevant financial relationships to disclose. Any conflicts have been resolved by the Journal in accordance with the Muscle & Nerve editorial process.

Mohamed Kazamel, MD; Amro Maher Stino, MD; Albert Gordon Smith, MD.
Availability: Retired
Cost: Member: $0.00
Non-Member: $25.00
Credit Offered:
No Credit Offered
2621 Superior Drive NW Rochester, MN 55901
Phone: 507.288.0100
Fax: 507.288.1225
Powered By